Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
excuse me Snupdawg casc has news that you thought would be
released pre-market on Friday, snup you are so right
it is impossible to time the market with exact precision
but your recent buys are looking
$$$$$$$$$$$$$$$$$
snupdawgoled relishing the moment
nice swing back up yesterday a leak? no volume was low
but nice to see us back at a buck pre split.
hopefully we get a surge pre market on friday
snupdawgoled
symposium,
we present after 5pm tomorrow wed
thursday may start to get a vibe
friday presentation on 1b trial 7:30 -9am pre market
casc about to rock?
or
re-newed selling?
to be continued
quite a see saw of pps
let's see if symposium wed-fri
will be nice catalyst for casc's inflection upwards
super whale bought huge at 92 cent level or 5.72 cent levels
snupdawgold
well a new day
still awaiting shortie to return with hammer today
after they suck in new buyers like yesterday,
hopefully,
we get some good news later next week
we present I believe on dec 6 and 7
next friday presentation is 730-9 am
of course I am looking for decisive pop friday and following
week on adventagious data.
snup
Man, I am being brought to the wood shed by casc shorties
today, You guys are blls to the metal, wow!
snup
You thought that was bad 5.04 low for the day,
man , I am on the wrong side of this stock.
They are shorting casc with abandon, hopefully my
hunch is right and they have good news coming from
symposium dec.5-7 to quiet the nerves of longs
snup
93 cents pre rs or 5.60 a share ouch
92 cents was where whale bought at
conference dec.5-7
snup
5.83 holding steady near .97 cents pre split
we got the symposium next wed thru friday
should be inflection point.
snupdawgoled
last day to get out pre rs
I think we get go up after symposiom dec 5-8
casc about to start attracting main stream investors
after 1:6 rs
snup
rs on tues morning same symbol
bought 24k more today, I think dec 6 and 7 symposium will
yield good news and with volatility of rs 1:6 it could yield
a couple of bucks movement to the upside.
casc has a 52 week high of 3 plus
a major purchase by a whale at 92 cents
play the ball where it is 1.03
snup dawg oled
Jnizz,
picked up a few today, rs before dec.31 52-week low 82
high about 1.81 seems like a great entry point.
around dec.5 reveals more data on lead drug Tan
looking for a bounce up on healthy volume pre-meeting
in sandiego, will decide then to hold thru split or not
if data still awesome.
snup
They will be announcing between a 5-11 to 1 split I believe. I say go for the 11 lol
When is are a split?
All bios down casc especially hit I'm buying
What is happening here?!?!?
Doesn't make much sense... even with good results the price drops. They are using the reverse split to get more institutional support so I don't understand what all the selling off is about?
What is happening here. Great results so why does the stock price keep dropping?
Buying CASC here
Can anyone tell me please if Monday's poster presentations are old news or new data not seen? I'm not sure of conference policy?
Agree great hold through EOY
Very nice. I bought 1000 shares when they relisted as Casc. Riding a little less then half of that now as freebies after the past few days.
This thing is gonna push 2-2.25 in the near future. Whoever bought 2 million shares the past few days is probably holding. Should move up quickly on any news about phase 2s.
Go onty oops I mean Casc lol
Reloading big with dip
Just trimmed 50% of position profits here
CASC formerly ONTY up over 20%
4x volume yesterday NO NEWS
Looks like a hedge is buying it up!
Casc up big on huge EOD and after hour trading!
This Investor Just Grabbed 25 Million Shares Of Cascadian Therapeutics
http://marketexclusive.com/investor-grabs-25-million-shares-cascadian-therapeutics-inc-usa-nasdaqcasc/9003/?icd1
CASC looking good going into Monday. Great ah action on Friday.
CASC: Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of Advanced HER2+ Metastatic Breast Cancer
Jun 29, 2016 08:00:00 (ET)
Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of Advanced HER2+ Metastatic Breast Cancer
SEATTLE, June 29, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the ONT-380 program in advanced HER2+ metastatic breast cancer has received Fast Track designation from the U.S. Food and Drug Administration ("FDA").
The Company is actively recruiting patients for a randomized, double-blind, placebo-controlled Phase 2 study, known as HER2CLIMB, evaluating ONT-380 in combination with trastuzumab and capecitabine for patients with advanced HER2+ metastatic breast cancer. This trial is expected to enroll up to 180 patients with and without brain metastases. ONT-380 is an oral, highly selective small molecule inhibitor of HER2.
"Fast Track designation recognizes the unmet medical need for this serious disease," said Scott Myers, President and CEO of Cascadian Therapeutics. "Many patients with metastatic HER2+ breast cancer will see their disease progress despite the availability and use of multiple targeted therapies. We are encouraged by the early evidence of systemic activity and activity against brain metastases, and the favorable tolerability profile with ONT-380 in combination studies."
The FDA established the Fast Track designation process to facilitate development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Through the Fast Track program, more frequent meetings may be scheduled with the FDA to discuss the drug's development plan and to ensure the collection of appropriate data needed to support approval. Additionally, the drug may qualify for accelerated approval and priority review and, at the time of a new drug application (NDA) filing, the drug candidate's sponsor may be eligible to submit completed sections of the NDA on a rolling basis before the complete application is submitted.
"Fast Track designation has the potential to reduce development time and cost associated with bringing a drug to patients," said Valerie Fauvelle, Director of Regulatory Affairs for Cascadian Therapeutics. "We look forward to working closely with the FDA to rapidly advance ONT-380 through the clinical development and regulatory process."
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Our lead product candidate, ONT-380, is an orally active and selective small molecule HER2 inhibitor, which has been studied in approximately 200 patients to date. Preliminary results from two ongoing Phase 1b studies of ONT-380 in combination showed promising systemic activity, a favorable safety profile and encouraging activity against brain metastases. Cascadian is also conducting a randomized, double-blind, placebo-controlled Phase 2 study called HER2CLIMB (ONT-380 + trastuzumab + capecitabine) in patients with locally advanced or metastatic HER2+ breast cancer previously treated with a taxane, trastuzumab, pertuzumab, and T-DM1. This study is expected to enroll 180 patients with and without brain metastases across approximately 100 clinical sites in the U.S., Canada, and Western Europe. For more information, visit www.ClinicalTrials.gov: NCT02614794. The Company is also developing a cell cycle inhibitor, Chk1, and plans to move the program forward through IND-enabling studies in 2017.
Forward-Looking Statements
In order to provide Cascadian Therapeutics' investors with an understanding of its current results and future prospects, this release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include Cascadian Therapeutics' expectations regarding clinical development activities, timing of additional data and potential benefits of its product candidates.
Forward-looking statements involve risks and uncertainties related to Cascadian Therapeutics' business and the general economic environment, many of which are beyond its control. These risks, uncertainties and other factors could cause Cascadian Therapeutics' actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing its product candidates, the adequacy of financing and cash, cash equivalents and investments, changes in general accounting policies, general economic factors, achievement of the results it anticipates from its preclinical development and clinical trials of its product candidates and its ability to adequately obtain and protect its intellectual property rights. Although Cascadian Therapeutics believes that the forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of Cascadian Therapeutics' risks and uncertainties, you are encouraged to review the documents filed with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Except as required by law, Cascadian Therapeutics does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.
Additional Information
Additional information relating to Cascadian Therapeutics can be found on EDGAR at www.sec.gov and on SEDAR at www.sedar.com.
Investor Contact:
Julie Rathbun
Rathbun Communications
206-769-9219
ir@cascadianrx.com
Tricia Truehart
The Trout Group
646-378-2953
ttruehart@troutgroup.com
Media Contact:
Amy Bonanno
BMC Communications
646-513-3117
abonanno@bmccommunications.com
(MORE TO FOLLOW) Dow Jones Newswires
June 29, 2016 08:00 ET (12:00 GMT)
CASC: Cascadian Therapeutics Has Gross Proceeds of $32.2M From Exercise of Over-Allotment Option
Cascadian Therapeutics Announces Exercise of Underwriters' Over-Allotment Option and Closing of $46.0 million Concurrent Offerings of Common Stock and Series D Convertible Preferred Stock
SEATTLE, June 28, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC) today announced that it has closed the previously announced underwritten public offering of 40,250,000 shares of its common stock at a price to the public of $0.80 per share for gross proceeds of $32.2 million. The shares include 5,250,000 shares of common stock sold pursuant to the over-allotment option granted by the Company to the underwriters, which option was exercised in full. In addition, Cascadian Therapeutics closed the previously announced offering of 17,250 shares of its Series D Convertible Preferred Stock at a price of $800.00 per share directly to affiliates of BVF Partners L.P., which are existing stockholders and affiliates of a member of the board of directors of Cascadian Therapeutics, for gross proceeds of $13.8 million.
Aggregate gross proceeds from both offerings, before deducting underwriting and placement agent discounts and commissions and expenses, was $46.0 million. The offerings were conducted as separate offerings by means of separate prospectus supplements, and neither the sale of Series D Convertible Preferred Stock nor the common stock offering was contingent upon the consummation of the other.
Each share of Series D Convertible Preferred Stock is non-voting and convertible into 1,000 shares of Cascadian Therapeutics common stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would beneficially own more than 19.99% of the common stock then outstanding, subject to adjustment. The Series D Convertible Preferred Stock will rank senior to all of the company's common stock, on parity with the Company's Series A, B and C Convertible Preferred Stock and junior to the Company's Class UA Preferred Stock. In the event of a liquidation, dissolution or winding up of the Company, holders of the Series D Convertible Preferred Stock will receive a payment equal to $0.0001 per share of Series D Convertible Preferred Stock before any proceeds are distributed to the holders of the common stock, pari passu with any distribution of proceeds to holders of the Series A, B and C Convertible Preferred Stock, and after any distribution of proceeds to holders of the Class UA Preferred Stock.
Cowen and Company, LLC acted as the sole book-running manager and Trout Capital LLC acted as a co-manager in the common stock offering. Cowen and Company, LLC and Trout Capital LLC acted as the placement agents in the registered direct offering.
Each of the offerings was made to purchasers pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission, or SEC. Prospectus supplements and accompanying prospectuses describing the terms of the offerings are filed with the SEC. Copies of the prospectus supplements and accompanying prospectuses may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806. Electronic copies of the prospectus supplements and accompanying prospectuses will also be available on the website of the SEC at http://www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities of Cascadian Therapeutics, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Investor and Media Relations Contact:
Julie Rathbun
Rathbun Communications
206-769-9219
ir@cascadianrx.com
(MORE TO FOLLOW) Dow Jones Newswires
June 28, 2016 16:01 ET (20:01 GMT)
Jun 28, 2016 16:01:00 (ET)
Likely futile U.K. petition for 2nd Brexit referendum tops 2 million http://on.mktw.net/28Vk27E
they can do both or either or for casc
yes finally came out casc
casc needs some good news soon
not sure if this is good or bad new name casc
thx
no mods for this board it seems
Board Moderators request the change:
How do I get a board name/symbol changed?
If you are the board's Moderator or an Assistant you can go to the Manage page and click Board Name/Ticker Change and fill in the requested information. These go into a queue that are reviewed by site Admins throughout the day.
Do Mods change symbol or start a new board?
(ONTY) Oncothyreon Inc. changes its name
http://www.streetinsider.com/Corporate+News/Oncothyreon+(ONTY)+Changes+Name+to+Cascadian+Therapeutics%3B+Will+Begin+Trading+Under+Ticker+CASC/11720500.html
Oncothyreon (ONTY) Changes Name to Cascadian Therapeutics; Will Begin Trading Under Ticker 'CASC'
Oncothyreon Inc. (Nasdaq: ONTY) (Nasdaq: CASC) announced that the Company is changing its name to Cascadian Therapeutics, Inc. and will trade on the NASDAQ Global Select Market under the new ticker symbol “CASC,” effective at market open on June 9, 2016.
The new name reflects the change in the Company’s focus from therapeutic vaccines to advancing targeted treatments for cancer. The Company’s lead product candidate, ONT-380, is an orally bioavailable, highly selective small molecule HER2 inhibitor being developed as a combination therapy to treat HER2+ advanced or metastatic breast cancer.
“We chose to implement a new name to emphasize our organization’s transformation and vision for the future,” said Scott Myers, President and CEO of Cascadian Therapeutics. “By incorporating the imagery of the Cascade Mountains, our goal was to highlight our Company’s heritage, but more importantly, to underscore our transition away from therapeutic vaccines to developing innovative targeted therapies for cancers, with a lead indication for metastatic HER2+ breast cancer. HER2CLIMB, our Phase 2 randomized, double-blind, placebo-controlled trial, was also named in the spirit of our mission to improve outcomes in this disease. We look forward to providing an update on this important program at our upcoming R&D Day.”
On June 14th at 2 p.m. Eastern, the Company will present updated data from the ongoing “Triplet” Phase 1b trial, in addition to the future product development plans for ONT-380, at the Company’s R&D Day in New York City. The webcast will be available on the Events and Presentations Page of the Company’s website at www.cascadianrx.com.
No action is required by stockholders with respect to the name change. The Company's common stock has been assigned a new CUSIP number of 14740B 101 in connection with the name change. Outstanding stock certificates are not affected by the name change and will not need to be exchanged.
Positive Phase 1 results
http://finance.yahoo.com/news/oncothyreon-presents-phase-1b-results-130000548.html
Oncothyreon Presents Phase 1b Results of ONT-380 in Combination with T-DM1 in HER2+ Metastatic Breast Cancer at ASCO
Encouraging results in ONT-380 combination therapy in patients with and without brain metastases
CHICAGO, June 05, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (ONTY), a clinical-stage biopharmaceutical company, today announced the presentation of clinical data on its lead product candidate, ONT-380, at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO). ONT-380 is a highly selective small molecule HER2 inhibitor being developed in combination to treat HER2+ advanced or metastatic breast cancer.
Data from a poster presentation (#513 “Efficacy Results of a Phase 1b Study of ONT-380, a CNS-Penetrant TKI, in Combination with T-DM1 in HER2+ Metastatic Breast Cancer (MBC), Including Patients with Brain Metastases”) showed promising safety and efficacy results in a Phase 1b study as treatment in patients with progressive disease who were previously treated with trastuzumab and a taxane.
“These results continue to demonstrate the potential of ONT-380 in the treatment of HER2+ breast cancer,” said Luke Walker, M.D., Vice President, Clinical Development. “The early evidence of systemic activity, combined with a favorable safety profile and encouraging activity against brain metastases, is supportive of further development of this combination.”
“Our internal team and advisors believe that these data are very intriguing and that the T-DM1 combination warrants further exploration,” commented Scott Myers, President and CEO. “However, given current resources and the development requirements in this setting, we will pursue this combination in cooperation with others or develop ourselves at a later date. Going forward, we remain focused on advancing our ongoing Phase 2 ‘Triplet’ trial with ONT-380 in combination with capecitabine and trastuzumab.”
Updated data from the ongoing “Triplet” Phase 1b trial and the future ONT-380 product development plan will be presented at the Company’s R&D Day on June 14th in New York City.
Shareholder meeting June 23
Q2 Earnings Aug 4 after market closes (unconfirmed)
according to Fidelity
Quarterly is out. The separation agreement with the previous CEO did cost 4.3 million, but at least it wasn't a continuing cost. Also, I like that ONT-380 research funding increased. Still liking this company for a long position.
Finally a nice move here today...patience pays!
no idea Killian, they are all a crap shoot, lotto play IMO
but why? must be some news driving the volume so high! any idea?
Followers
|
61
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
792
|
Created
|
05/16/06
|
Type
|
Free
|
Moderators |
company web-site - http://www.oncothyreon.com
recent event / CC - http://ir.oncothyreon.com/events.cfm -
Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. We are currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Our pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications. Oncothyreon is headquartered in Bellevue, Washington. The Company is traded on the NASDAQ National Market under the symbol ONTY and on the Toronto Stock Exchange under the symbol ONY. We are The Cancer Vaccine People(TM).
Stimuvax
ONTY's drug Stimuvax, in partnership with Merck KGaa, is now in large Phase 3 Pivotal Trial program for NSCLC:
Phase III NSCLC (Lung) "START" Trial - http://www.clinicaltrials.gov/ct2/show/NCT00409188
Phase III NSCLC "INSPIRE" Trial (Asia) - http://www.clinicaltrials.gov/ct2/show/NCT01015443
Phase II NSCLC w/Avastin Trial - http://www.clinicaltrials.gov/ct2/show/NCT00828009
Phase I/II NSCLC Trial in Japan - http://www.clinicaltrials.gov/ct2/show/NCT00960115
Phase IV Long-Term Safety Trial - http://www.clinicaltrials.gov/ct2/show/NCT01423760
Phase II HDPC Trial - http://bethesdatrials.cancer.gov/clinical-research/search_detail.aspx?ProtocolID=NCI-11-C-0247
Pipe-Line - http://www.oncothyreon.com/pipeline/overview.html
Remaining Pipe-Line -
ONT-10 - http://www.oncothyreon.com/pipeline/vaccines/ONT-10/overview.html
PX-866 - http://www.oncothyreon.com/pipeline/small/PX-866/overview.html
Start of Trial with Taxotere - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=526661
Start of Trial with Erbitux - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=537953
PRESS RELEASES
Oncothyreon Initiates Phase 2 Trial of its PI-3 Kinase Inhibitor PX-866 in Patients with Glioblastoma - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=561867
Oncothyreon Presents Preclinical Data for ONT-10 and PX-866 at American Association for Cancer Research - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=561521
Oncothyreon Announces Publication of Safety & Survival Data From Stimuvax Phase 1/2 NSCLC Trial - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=515788
Oncothyreon Initiates Phase 1/2 Trial of its PI-3 Kinase Inhibitor PX-866 in Combination with Cetuximab - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=537953
Oncothyreon announces that Merck Serono is resuming the Stimuvax clinical program in lung cancer - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=480296
Oncothyreon announces temporary suspension of Stimuvax clinical trials - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=453976
Oncothyreon announces STRIDE Phase 3 BC trial - June 22, 2009 http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38926533
Oncothyreon announces clinical data at ASCO - May 30, 2009 - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38259984
Oncothyreon announces development plans - Dec. 18, 2008 - http://biom.client.shareholder.com/releasedetail.cfm?ReleaseID=355043
Merck KGaA buys manufacturing rights for Stimuvax - Dec. 18, 2008 - http://biom.client.shareholder.com/releasedetail.cfm?ReleaseID=355037
ONTY/Merck KGaA amend agreements - Aug 8, 2007http://www.marketwatch.com/news/story/biomira-merck-kgaa-sign-amended/story.aspx?guid=%7B43FD62A1%2D....
MEDICAL PRESENTATIONS
ASCO 2007 Stimuvax Abstract - http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32165
"16 pts were evaluated for this interim safety analysis ..........As of September 2006, 10 pts were still on study treatment."
ASCO 2008 Stimuvax Abstract - http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34755
"The 2-year survival rate of 64% ....compares favorably with previously reported survival for chemoradiation in stage III NSCLC."
ASCO 2009 Stimuvax Abstract - http://www.abstract.asco.org/AbstView_65_31704.html
"a remarkable # of pts received prolonged treatment...16 pts received L-BLP25 for 2.0-7.7 years, 10 pts were treated for >5 years."
COMPLETE MEDICAL PAPERS
Paper summarizing all Stimuvax trials to date - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39761211
Publication of Data From Phase 1/2 NSCLC Trial - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=515788
A Peptide Vaccine Strategy in NSCLC - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39627241
Phase IIb Trial in NSCLC Stage IIIB and IV - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39099793
"The greatest difference in survival was observed in stage IIIB LR patients (adjusted HR = 0.524; 95% CI, 0.261 to 1.052; P = .069)"
- Fig 3. Overall survival by study arm - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F3
- Fig 4. Survival analysis for stage IIIB with MFE or stage IV patients - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F4
- Fig 5. Survival analysis for stage IIIB locoregional patients - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F5
Detailed Description of START Trial - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39062424
First Interim Look - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58060227
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |